Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.

Journal of acquired immune deficiency syndromes (1999) - 1 Mar 2023

Wembulua Bruce Shinga, Valin Nadia, Lambert-Niclot Sidonie, Nerozzi-Banfi Estelle, Chiarabini Thibault, Meynard Jean Luc, Lacombe Karine

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Anti-Retroviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Infections

Share to Mutation

Share to Pyridones

Share to Rilpivirine

Source

Identifiers

PMID: 36729654
DOI: 10.1097/QAI.0000000000003148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.PMID 36729654Read ↗

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settingsSemantic proximity Read ↗

Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in São Paulo, Brazil.Semantic proximity Read ↗

HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.Semantic proximity Read ↗

Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.Semantic proximity Read ↗

An updated guide to genotype interpretation.Semantic proximity Read ↗

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsSemantic proximity Read ↗

Development of a genotyping flow sheet for appropriate antiretroviral therapy.Semantic proximity Read ↗

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.Semantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitorsSemantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.